We are live on ! Find out more
DYN icon

Dyne Therapeutics

90 hedge funds and large institutions have $321M invested in Dyne Therapeutics in 2022 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 26 increasing their positions, 31 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more funds holding in top 10

Funds holding in top 10: 45 (+1)

2.05% less ownership

Funds ownership: 92.43%90.39% (-2%)

4% less funds holding

Funds holding: 9490 (-4)

16% less repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 31

18% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 11

30% less capital invested

Capital invested by funds: $457M → $321M (-$136M)

Holders
90
Holders Change
-4
Holders Change %
-4.26%
% of All Funds
1.52%
Holding in Top 10
5
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+25%
% of All Funds
0.08%
New
9
Increased
26
Reduced
31
Closed
11
Calls
$1K
Puts
Net Calls
+$1K
Net Calls Change
-$6K
Name Holding Trade Value Shares
Change
Change in
Stake
AllianceBernstein
26
AllianceBernstein
Tennessee
$1.71M +$450K +65,331 +36%
HS
27
HighVista Strategies
Massachusetts
$1.66M +$504K +73,176 +43%
Morgan Stanley
28
Morgan Stanley
New York
$1.57M -$527K -76,493 -25%
UOC
29
UBS O'Connor
Illinois
$1.56M +$1.57M +227,358 New
EC
30
EcoR1 Capital
California
$1.48M
N
31
Nuveen
North Carolina
$1.38M +$399K +57,863 +41%
Charles Schwab
32
Charles Schwab
California
$1.23M -$91.8K -13,324 -7%
ACH
33
ArrowMark Colorado Holdings
Colorado
$1.16M
Bank of New York Mellon
34
Bank of New York Mellon
New York
$752K -$17.8K -2,586 -2%
HMC
35
Harvard Management Company
Massachusetts
$737K
Balyasny Asset Management
36
Balyasny Asset Management
Illinois
$679K +$681K +98,866 New
Wellington Management Group
37
Wellington Management Group
Massachusetts
$653K
Renaissance Technologies
38
Renaissance Technologies
New York
$627K +$334K +48,500 +114%
Dimensional Fund Advisors
39
Dimensional Fund Advisors
Texas
$568K +$224K +32,512 +65%
IBT
40
International Biotechnology Trust
United Kingdom
$563K -$3.25M -472,135 -99%
Barclays
41
Barclays
United Kingdom
$547K +$415K +60,313 +314%
Fidelity Investments
42
Fidelity Investments
Massachusetts
$500K +$455 +66 +0.1%
Tudor Investment Corp
43
Tudor Investment Corp
Connecticut
$481K +$103K +14,932 +27%
Goldman Sachs
44
Goldman Sachs
New York
$454K -$86.2K -12,514 -16%
Swiss National Bank
45
Swiss National Bank
Switzerland
$418K +$40.6K +5,900 +11%
RhumbLine Advisers
46
RhumbLine Advisers
Massachusetts
$305K +$47.8K +6,938 +19%
Ensign Peak Advisors
47
Ensign Peak Advisors
Utah
$275K
First Trust Advisors
48
First Trust Advisors
Illinois
$254K -$6.46K -937 -2%
T. Rowe Price Associates
49
T. Rowe Price Associates
Maryland
$251K +$703 +102 +0.3%
California State Teachers Retirement System (CalSTRS)
50
California State Teachers Retirement System (CalSTRS)
California
$242K +$18.7K +2,711 +8%

DYN Hedge Fund Activity: Q2 2022 in Review

90 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Dyne Therapeutics (DYN) for Q2 2022, worth a combined $321M — down 30% from $457M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of DYN and 9 opened new positions — a net loss of 2 holders — while 31 trimmed existing stakes and 26 added.

The largest buyer was Franklin Resources, adding an estimated $3.92M. The largest seller was Norges Bank, exiting entirely with an estimated $5.78M sold.

  • 90 institutional investors held Dyne Therapeutics (DYN) as of Q2 2022, down from 94 in Q1 2022.
  • Funds reported $321M of Dyne Therapeutics stock for Q2 2022, down 30% quarter-over-quarter.
  • 9 funds opened new Dyne Therapeutics positions in Q2 2022 and 11 closed out, a net change of -2 holders.
  • The largest Dyne Therapeutics buyer in Q2 2022 was Franklin Resources, an estimated $3.92M added.
  • The largest Dyne Therapeutics seller in Q2 2022 was Norges Bank, an estimated $5.78M sold.

Based on aggregated 13F filings for Q2 2022.